Back

Synthetic HRV assessment of autonomic modulation effects induced by empaglifozin added to optimized therapy in a patient with post-COVID paroxysmal atrial fibrillation-induced heart failure and normal

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in chronic heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Donatella Brisinda

Catholic University of the Sacred Heart, Rome (Italy)

3 More presentations in this session

Presentation thumbnail
Acetazolamide as an adjunct to loop diuretics in decongesting patients with acute decompensated heart failure: a systematic review and meta-analysis
Doctor J. Interior (Quezon, PH)
Abstract Slides Video
Presentation thumbnail
Pharmacological treatments in adults with chronic heart failure: a systematic review and component network meta-analysis
Miss X. Zou (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients
Professor O. Hanon (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in chronic heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Cardiac reverse remodeling and SGLT2ii: insight from hemodynamic forces analysis
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources